Medtech titan St. Jude Medical slides 7% after the FDA releases a report slamming the device maker's Durata pacemaker leads.
MASSDEVICE ON CALL — Medical device maker St. Jude Medical's (NYSE:STJ) shares lost more than 10% in one day after the FDA released a report detailing potential issues with the tech giant's Durata pacemaker leads.
STJ shares on Wednesday, November 21, opened at $33.76 prior to the publication of the FDA's report. Shares tumbled 7.1% by the end of the day, closing at $31.76 and along the way notching a new 52-week low of $30.25, a 10.4% dip.
The FDA's report detailed 11 problems with manufacturing at St. Jude's Sylar, Calf., plant, which manufactures the company's Durata pacemaker leads.
Investors are watching closely for signs of problems with the next-generation Durata leads after the St. Paul, Minn.-based medical device company recalled some of its Riata leads last year. Last month CEO Daniel Starks cautioned that St. Jude risked a warning from the federal watchdog agency over the Sylmar plant.
STJ shares regained some of their lost value, closing at $32.03 on Friday, still a 5.1% loss from Thursday's open.
Airport X-rays versus medical devices
Airport body and luggage X-ray scanners may damage some diabetes devices, including insulin pumps and continuous glucose monitors, according to editors of the journal Diabetes Technology & Therapeutics.
BD, Rite Aid team up with EPA for safer needles
Healthcare company Becton Dickinson & Co. (NYSE:BDX) teamed up with Rite Aid to develop a program with the Dept. of Environmental Protection, aiming to reduce injuries associated with medical sharps such as needles and other devices.
Coloplast posts its 1st profits decline in 7 years on mounting legal costs stemming from U.S. product...
Shares of Smith & Nephew are up today on solid 3rd-quarter results, including 6% growth for its U...
Here's a look at some of the top Wall Street stories for medical device companies this week:...
Abiomed says it's come to an agreement with the FDA on an indication for its flagship Impella 2.5...
Medtronic and Covidien say their pending, $43 billion merger is expected to close in early 2015.